Skip to main content

Table 6 Multivariate analysis estimating risk of haemoglobin drop from baseline to ≥2 g/dL during different post-treatment follow-up visits

From: Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali

 

Day 7 (2,657)

Day 14 (n=4,638)

Day 28 (n=4,082)

 

OR* (95% CI)

p

OR*(95% CI)

p

OR* (95% CI)

p

Covariates**

      

AL

0.51 (0.28-0.90)

0.02

1.33 (0.95-1.87)

0.10

0.86 (0.54-1.39)

0.55

AS+partners

0.70 (0.52-0.94)

0.02

0.95 (0.69-1.32)

0.78

0.96 (0.63-1.44)

0.83

AS

1.36 (0.97-1.92)

0.08

0.99 (0.61-1.59)

0.96

1.07 (0.58-1.96)

0.83

<5 years old

0.87 (0.68-1.11)

0.25

0.82 (0.65-1.04)

0.10

0.82 (0.60-1.12)

0.21

P.f. day 0

1.80 (1.41-2.30

<0.001

1.68 (1.33-2.12)

<0.001

1.30 (0.96-.75)

0.09

Treat fail

1.43 (0.88-2.32)

0.15

1.63 (1.13-2.38)

0.01

2.03 (1.44-2.87)

<0.001

  1. Note: *OR is the odds ratio obtained from generalized linear and latent mixed model with binomial family using site as random effect;
  2. **Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥ 5 years old for the age group, the 28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for day 28.